Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 41 of 116

  1. CSET n° 2020/3210

    The George Institute

    Untreated small triple negative breast cancer

    phase 2 other active

    1 trial

  2. CSIIT-Q115

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. CT-011

    Teva Pharma GmbH

    Primary Hepatocellular Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  5. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Renal Cell Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  6. CT7001, PF-07850327 round

    Pfizer Australia Pty Ltd

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  7. CTX-009

    Compass Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  8. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  9. CTX112

    S.A.

    B-cell Lymphoma

    phase 2 mab active

    1 trial

  10. CTX131

    S.A.

    Clear Cell Renal Cell Carcinoma

    phase 2 mab completed

    1 trial

  11. CTX131

    S.A.

    T Cell Lymphoma

    phase 2 mab completed

    1 trial

  12. CUE-101

    Cue Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. CUE-101

    Cue Biopharma

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. CX-072

    CytomX Therapeutics

    Solid Tumor

    phase 2 small molecule terminated

    2 trials

  15. CX-2009

    CytomX Therapeutics

    Neoplasms

    phase 2 small molecule completed

    1 trial

  16. CX-2009

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule terminated

    1 trial

  17. CX-2029

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  18. CYCAD-1(D8470C00001)

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  19. CYTB323A12101

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  20. Cabozantinib

    Takeda

    Advanced Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  21. Cabozantinib

    Takeda

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  22. Cabozantinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  23. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  24. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  25. Cadonilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  26. Calcio levofolinato Teva Generics polvere per...

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  27. Calquence 100 mg film-coated tablets

    AstraZeneca

    mantle cell lymphoma (MCL)

    phase 2 small molecule active

    1 trial

  28. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  29. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  30. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  31. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  32. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  33. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  34. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  35. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  36. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  37. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adrenal Cortical Carcinoma

    phase 2 small molecule active

    1 trial

  38. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  39. Camrelizumab Plus Apatinib

    Nanjing Zenshine Pharmaceuticals

    Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  40. Camrelizumab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  41. Camrelizumab plus apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  42. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  43. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  44. Capecitabine

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  45. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  46. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  47. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  48. Capecitabine

    xie congying

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.